Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Michael Ackland Medically reviewed by Dr
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
The mechanism of action, involving natural beta-3 adrenergic receptors and lipolytic pathways, suggests that chronic use is unlikely to produce novel safety concerns beyond what was observed in clinical trials
Cross-check against manual math: While the calculator is designed for accuracy, it is good practice to occasionally run the math manually to confirm your understanding of the formulas
We say, YOU MATTER, because you are significant
In laboratory settings this can translate to a more pronounced experimental response
US$ 27.17
US$ 26.00
US$ 29.50
US$ 26.74
US$ 23.39
US$ 24.24
US$ 28.45
